FDA clears Novartis’ oral drug for chronic hives
Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Novartis Pharma AG Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 &…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1…